retatrutide obesity trial results just delivered the first top-line Phase 3 for a triple agonist in — and the findings from TRIUMPH-4 are striking👇 Retatrutide: A Triple Agonist Shaping

As the disease progressed, patients would often switch or add therapies to maintain control

Its crucial to remember that individual responses to medications vary significantly

Written by Jordan Weiss and reviewed by Daniel Angerbauer, DO, and republished with permission from Atria Health and Research Institute

Those on placebo usually experienced an increase in craving in the afternoon or evening

Separately, there is a proposed class action lawsuit filed by a drug wholesaler alleging anticompetitive conduct by Novo Nordisk to delay generic Victoza entry into the market, seeking damages on behalf of purchasers rather than patients injured by the drug

Exenatide effects on statin pharmacokinetics and lipid response